Juno therapeutics has shifted its focus toward the development of JCAR017 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) after a series of toxicity-related setbacks culminated in the need to halt the development of JCAR015, according to a statement from the company. Both are CD19-directed CAR T-cell therapies.
"Looking forward into 2017, we continue to be optimistic about the progress we are making with JCAR017 and our pipeline more broadly," Bishop said. "We expect 2017 will be a data-rich year of key insights, based on up to 20 ongoing trials by year end, and we plan to present data from these trials as appropriate throughout the year.”
- Abramson JS, Palomba L, Gordon LI, et al. Transcend NHL 001: immunotherapy with the CD19-directed CAR T-cell product JCAR017 results in high complete response rates in relapsed or refractory b-cell non-Hodgkin lymphoma. Presented at: 58th American Society of Hematology Annual Meeting; San Diego, CA; December 3-6, 2016. Abstract 4192.
- Gardner R, Finney O, Smithers H, et al. CD19CAR T Cell Products of Defined CD4:CD8 Composition and Transgene Expression Show Prolonged Persistence and Durable MRD-Negative Remission in Pediatric and Young Adult B-Cell ALL. Presented at: 58th American Society of Hematology Annual Meeting; San Diego, CA; December 3-6, 2016. Abstract 219.
- Park JH, Riviere I, Wang X, et al. Impact of disease burden on long-term outcome of 19-28z CAR modified T cells in adult patients with relapsed B-ALL. J Clin Oncol. 2016;34 (suppl; abstr 7003).
... to read the full story